HELIO ELKIS
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Psiquiatria, Faculdade de Medicina - Docente
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
58 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 58
conferenceObject MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA(2018) HIGUCHI, Cinthia; COGO-MOREIRA, Hugo; BERTOLUCCI, Bruno; CORRELL, Christoph U.; NOTO, Cristiano; CORDEIRO, Quirino; FREITAS, Rosana; ELKIS, Helio; BELANGERO, Sintia I.; BRESSAN, Rodrigo A.; GADELHA, AryconferenceObject EFFICACY AND SAFETY OF TRANSCRANIAL DIRECT CURRENT STIMULATION FOR TREATING NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: THE FOLLOW-UP PHASE(2020) VALIENGO, Leandro; SERPA, Mauricio; ELKIS, Helio; BILT, Martinus Van de; LACERDA, Acioly; GATTAZ, Wagner; BRUNONI, AndreconferenceObject COMPARISON OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FACTOR STRUCTURE IN PATIENTS WITH REFRACTORY VERSUS NON REFRACTORY SCHIZOPHRENIA(2015) FREITAS, Rosana Ramos; VIZZOTTO, Adriana Dias Barbosa; AVRICHIR, Belquiz; SCENES, Silvia; SA JUNIOR, Antonio Reis de; SANTOS, Bernardo Pereira; LOUZA NETO, Mario Rodrigues; ELKIS, Helio- Meta-analyses of cavum septum pellucidum in mood disorders in comparison with healthy controls or schizophrenia(2018) BERALDI, Gabriel H.; PRADO, Kelly S.; AMANN, Benedikt L.; RADUA, Joaquim; FRIEDMAN, Lee; ELKIS, HelioThe cavum septum pellucidum (CSP) is a neurodevelopmental abnormality significantly more prevalent in subjects with schizophrenia (SCZ) than in healthy controls (HC). Using meta-analyses, we tested the hypotheses whether CSP would be more frequent in subjects with mood disorders when compared with HC or SCZ. We performed a search in MEDLINE and EMBASE followed by 10 meta-analyses of magnetic resonance imaging studies which examined the association of CSP in bipolar disorders (BD), major depressive disorder (MDD) or mood disorders (MD; considering MDD and BD combined) with either HC or SCZ. Nine studies were included, comprising 692 cases (363 with BD, 182 with MDD and 147 with MD), 463 with SCZ and 630 HC. CSP of any size was significantly associated with BD (OR = 2.07, 95% CI: 1.48-2.90) when compared with HC. Large CSP showed a trend to be associated with BD when compared with HC, but the association was not statistically significant (OR = 1.92, 95% CI 0.64-5.78). Large CSP was significantly associated with subjects with SCZ when compared with subjects with MD (OR = 0.57, 95% CI: 0.36-0.92). There was no association between CSP and MDD in comparison to HC or subjects with SCZ. Cortical structures are known to be altered in mood disorders. The present metanalysis found that certain midline brain abnormalities, such as CSP, are also associated with BD. (c) 2018 Published by Elsevier B.V.
- ECT versus Sham for clozapine-resistant schizophrenia: A secondary analysis of a pilot study based on PANSS-30 individual items(2020) MELZER-RIBEIRO, Debora Luciana; GRILLI-TISSOT, Maria Cristina Ribeiro; ELKIS, Helio
- RANDOMIZED AND CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF OCCUPATIONAL THERAPY IN THE REHABILITATION OF EXECUTIVE FUNCTIONS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA(2019) VIZZOTTO, Adriana; CELESTINO, Diego; BUCHAIN, Patricia; OLIVEIRA, Alexandra; OLIVEIRA, Graca; SARNO, Elaine Di; NAPOLITANO, Isabel; ELKIS, Helio
- Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial(2021) BULUBAS, Lucia; GOERIGK, Stephan; GOMES, July S.; BREM, Anna-Katharine; CARVALHO, Juliana B.; PINTO, Bianca S.; ELKIS, Helio; GATTAZ, Wagner F.; PADBERG, Frank; BRUNONI, Andre R.; VALIENGO, LeandroCognitive deficits and negative symptoms in schizophrenia are associated with poor functional outcomes and limited in terms of treatment. The Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) trial has shown efficacy of transcranial direct current stimulation (tDCS) for improving negative symptoms. In this secondary analysis, we investigate its effects on cognitive performance. In STARTS, a double-blinded, sham controlled, randomized clinical trial, patients were treated with twice-daily, 20-min, 2-mA fronto-temporal tDCS over 5 days or sham-tDCS. In 90 patients, we evaluated the cognitive performance up to 12 weeks post-treatment. We found that active-tDCS showed no beneficial effects over sham-tDCS in any of the tests. Based on a 5-factor cognitive model, improvements of executive functions and delayed memory were observed in favor of shamtDCS. Overall, the applied active-tDCS protocol, primarily designed to improve negative symptoms, did not promote cognitive improvement. We discuss possible protocol modification potentially required to increase tDCS effects on cognition. ClinicalTrials.gov identifier: NCT02535676
- Treatment of Negative Symptoms of Schizophrenia With tDCS (Transcranial Direct Current Stimulation): A Randomized, Sham-Controlled, Double-Blinded Clinical Trial(2018) VALIENGO, Leandro; BILT, Martinus Theodorus van de; SERPA, Mauricio; GORDON, Pedro; HELKIS, Helio; GATTAZ, Wagner Farid; LACERDA, Acioly; BRUNONI, Andre
- Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-report(2021) DAMIANO, Rodolfo Furlan; AVRICHIR, Belquiz S.; MELZER-RIBEIRO, Debora L.; SALLET, Paulo Clemente; ELKIS, HelioThis is a case description of a patient with clozapine and ECT resistance schizophrenia with several suicide attempts. We discussed evidence-based clinical decisions to deal with such conditions.
- Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology(2017) HOWES, Oliver D.; MCCUTCHEON, Rob; AGID, Ofer; BARTOLOMEIS, Andrea de; BEVEREN, Nico J. M. van; BIRNBAUM, Michael L.; BLOOMFIELD, Michael A. P.; BRESSAN, Rodrigo A.; BUCHANAN, Robert W.; CARPENTER, William T.; CASTLE, David J.; CITROME, Leslie; DASKALAKIS, Zafiris J.; DAVIDSON, Michael; DRAKE, Richard J.; DURSUN, Serdar; EBDRUP, Bjorn H.; ELKIS, Helio; FALKAI, Peter; FLEISCHACKER, W. Wolfgang; GADELHA, Ary; GAUGHRAN, Fiona; GLENTHOJ, Birte Y.; GRAFF-GUERRERO, Ariel; HALLAK, Jaime E. C.; HONER, William G.; KENNEDY, James; KINON, Bruce J.; LAWRIE, Stephen M.; LEE, Jimmy; LEWEKE, F. Markus; MACCABE, James H.; MCNABB, Carolyn B.; MELTZER, Herbert; MOELLER, Hans-Juergen; NAKAJIMA, Shinchiro; PANTELIS, Christos; MARQUES, Tiago Reis; REMINGTON, Gary; ROSSELL, Susan L.; RUSSELL, Bruce R.; SIU, Cynthia O.; SUZUKI, Takefumi; SOMMER, Iris E.; TAYLOR, David; THOMAS, Neil; UCOK, Alp; UMBRICHT, Daniel; WALTERS, James T. R.; KANE, John; CORRELL, Christoph U.Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. Results: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting ofminimumadherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients. Conclusions: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.